Zobrazeno 1 - 2
of 2
pro vyhledávání: '"MTOR Inhibitors/pharmacology"'
Autor:
Anne E. Willis, Laura McDonald, George Skalka, Andrew D. Campbell, Heather McKinnon, Kevin M. Haigis, John R. P. Knight, Sebastian May-Wilson, Kathryn Gilroy, William J. Faller, Emma Stanway, Leah Officer, Rachael C. L. Smith, Joshua D.G. Leach, Joseph A. Waldron, Rachel A. Ridgway, Nicola Valeri, Ewan M. Smith, Arafath Kaja Najumudeen, Nahum Sonenberg, Joanne Edwards, Rene Jackstadt, Ana Teodósio, John Le Quesne, Dustin J. Flanagan, Anne Cheasty, Georgios Kanellos, Kerri McArthur, Christopher G. Proud, Constantinos Alexandrou, Georgios Vlachogiannis, Neil P. Jones, Nikola Vlahov, Owen J. Sansom, Kathryn Af Pennel, Craig MacKay, Martin E. Swarbrick, Martin Bushell
Publikováno v:
Knight, J R P, Alexandrou, C, Skalka, G L, Vlahov, N, Pennel, K, Officer, L, Teodosio, A, Kanellos, G, Gay, D M, May-Wilson, S, Smith, E M, Najumudeen, A K, Gilroy, K, Ridgway, R A, Flanagan, D J, Smith, R C L, McDonald, L, MacKay, C, Cheasty, A, McArthur, K, Stanway, E, Leach, J D, Jackstadt, R, Waldron, J A, Campbell, A D, Vlachogiannis, G, Valeri, N, Haigis, K M, Sonenberg, N, Proud, C G, Jones, N P, Swarbrick, M E, McKinnon, H J, Faller, W J, Quesne, J L, Edwards, J, Willis, A E, Bushell, M & Sansom, O J 2021, ' MNK Inhibition Sensitizes KRAS-Mutant Colorectal Cancer to mTORC1 Inhibition by Reducing eIF4E Phosphorylation and c-MYC Expression ', Cancer discovery, vol. 11, no. 5, pp. 1228-1247 . https://doi.org/10.1158/2159-8290.CD-20-0652
KRAS-mutant colorectal cancers are resistant to therapeutics, presenting a significant problem for ∼40% of cases. Rapalogs, which inhibit mTORC1 and thus protein synthesis, are significantly less potent in KRAS-mutant colorectal cancer. Using Kras-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4b093ca20383c7ab94bac414895dbf3
https://doi.org/10.1158/2159-8290.CD-20-0652
https://doi.org/10.1158/2159-8290.CD-20-0652
Autor:
Shao-Pei Hung, Wen-Chin Lee, Hsiang-Hao Hsu, Jin-Bor Chen, You-Ying Chau, Terry Ting-Yu Chiou
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 144, Iss, Pp 112349-(2021)
Chioua, T T-Y, Chau, Y-Y, Chen, J-B, Hsu, H-H, Huang, S-P & Lee, W-C 2021, ' Rapamycin attenuates PLA2R activation-mediated podocyte apoptosis via the PI3K/AKT/mTOR pathway ', Biomedicine and Pharmacotherapy, vol. 144 . https://doi.org/10.1016/j.biopha.2021.112349
Chioua, T T-Y, Chau, Y-Y, Chen, J-B, Hsu, H-H, Huang, S-P & Lee, W-C 2021, ' Rapamycin attenuates PLA2R activation-mediated podocyte apoptosis via the PI3K/AKT/mTOR pathway ', Biomedicine and Pharmacotherapy, vol. 144 . https://doi.org/10.1016/j.biopha.2021.112349
Membranous nephropathy (MN) is the most common cause of nephrotic syndrome in adults without diabetes. Primary MN has been associated with circulating antibodies against native podocyte antigens, including phospholipase A2 receptor (PLA2R); however,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b9d35f5abc372da2d816d2bcd3713e5
https://doi.org/10.1016/j.biopha.2021.112349
https://doi.org/10.1016/j.biopha.2021.112349
